Evidence map›Paper›PMID 22618666›Full record

ArticleMedical oncology (Northwood, London, England)2012

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population.

Sara Tomei, Sharon Adams, Lorenzo Uccellini, Davide Bedognetti, Valeria De Giorgi, Narnygerel Erdenebileg, Maria Libera Ascierto, Jennifer Reinboth, Qiuzhen Liu, Generoso Bevilacqua and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. A Case Study on PPM1D and 9 Other Shared Germline Alterations in a Family.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  3. Review
  4. Variations inMolecular and clinical oncology · 2022
    Article
  5. Association ofAging · 2019
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Sara TomeiDivision of Surgical, Molecular, and Ultrastructural Pathology, Section of Molecular Pathology, University of Pisa and Pisa University Hospital, 56100, Pisa, Italy. tomeis@mail.nih.gov
Sharon Adams
Lorenzo Uccellini
Davide Bedognetti
Valeria De Giorgi
Narnygerel Erdenebileg
Maria Libera Ascierto
Jennifer Reinboth
Qiuzhen Liu
Generoso Bevilacqua
Ena Wang
Chiara Mazzanti
Francesco M Marincola
National Institutes of Health Clinical Center · USUniversity of Pisa · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITUniversity of Würzburg · DE

Funding

Immunogenetic Study of Infectious Diseases and CancerZ01CL002118 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2007 to 2008
$1.4M
Immunogenetic Study of Infectious Diseases and CancerZIACL002118 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2009 to 2012
$0k
Intramural NIH HHS Z01 CL002118
6 · The paper itself

Abstract

HRAS belongs to the RAS genes superfamily. RAS genes are important players in several human tumors and the single-nucleotide polymorphism rs12628 has been shown to contribute to the risk of bladder, colon, gastrointestinal, oral, and thyroid carcinoma. We hypothesized that this SNP may affect the risk of cutaneous melanoma as well. HRAS gene contains a polymorphic region (rs112587690), a repeated hexanucleotide -GGGCCT- located in intron 1. Three alleles of this region, P1, P2, and P3, have been identified that contain two, three, and four repeats of the hexanucleotide, respectively. We investigated the clinical impact of these polymorphisms in a case-control study. A total of 141 melanoma patients and 118 healthy donors from the North America Caucasian population were screened for rs12628 and rs112587690 polymorphisms. Genotypes were assessed by capillary sequencing or fragment analysis, respectively, and rs12628 CC and rs112587690 P1P1 genotypes significantly associated with increased melanoma risk (OR = 3.83, p = 0.003; OR = 11.3, p = 0.033, respectively), while rs112587690 P1P3 frequency resulted significantly higher in the control group (OR = 0.5, p = 0.017). These results suggest that rs12628 C homozygosis may be considered a potential risk factor for melanoma development in the North American population possibly through the linkage to rs112587690.

Indexed as

Genetic Predisposition to DiseaseGenotypeHumansMelanomaNorth AmericaPolymorphism, Single NucleotideProto-Oncogene Proteins p21(ras)Reverse Transcriptase Polymerase Chain ReactionRisk FactorsSkin NeoplasmsWhite PeopleHRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID22618666
PMCPMC3505523
OpenAlexW2063309049

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.